Literature DB >> 31760463

Molecular mechanism of olesoxime-mediated neuroprotection through targeting α-synuclein interaction with mitochondrial VDAC.

Amandine Rovini1,2, Philip A Gurnev1, Alexandra Beilina3, María Queralt-Martín1, William Rosencrans1,4, Mark R Cookson3, Sergey M Bezrukov1, Tatiana K Rostovtseva5.   

Abstract

An intrinsically disordered neuronal protein α-synuclein (αSyn) is known to cause mitochondrial dysfunction, contributing to loss of dopaminergic neurons in Parkinson's disease. Through yet poorly defined mechanisms, αSyn crosses mitochondrial outer membrane and targets respiratory complexes leading to bioenergetics defects. Here, using neuronally differentiated human cells overexpressing wild-type αSyn, we show that the major metabolite channel of the outer membrane, the voltage-dependent anion channel (VDAC), is a pathway for αSyn translocation into the mitochondria. Importantly, the neuroprotective cholesterol-like synthetic compound olesoxime inhibits this translocation. By applying complementary electrophysiological and biophysical approaches, we provide mechanistic insights into the interplay between αSyn, VDAC, and olesoxime. Our data suggest that olesoxime interacts with VDAC β-barrel at the lipid-protein interface thus hindering αSyn translocation through the VDAC pore and affecting VDAC voltage gating. We propose that targeting αSyn translocation through VDAC could represent a key mechanism for the development of new neuroprotective strategies.

Entities:  

Keywords:  Channel reconstitution; Fluorescent correlation spectroscopy; Mitochondria; Planar lipid membrane; Proximity ligation assay; SH-SY5Y cells; VDAC-facilitated protein translocation; Voltage gating; Voltage-dependent anion channel

Mesh:

Substances:

Year:  2019        PMID: 31760463      PMCID: PMC7244372          DOI: 10.1007/s00018-019-03386-w

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  68 in total

Review 1.  Genetics of Synucleinopathies.

Authors:  Robert L Nussbaum
Journal:  Cold Spring Harb Perspect Med       Date:  2018-06-01       Impact factor: 6.915

Review 2.  Alpha-Synuclein in Peripheral Tissues in Parkinson's Disease.

Authors:  Ling-Yan Ma; Gen-Liang Liu; Dong-Xu Wang; Mei-Mei Zhang; Wen-Yi Kou; Tao Feng
Journal:  ACS Chem Neurosci       Date:  2019-02-11       Impact factor: 4.418

3.  Monomeric Alpha-Synuclein Exerts a Physiological Role on Brain ATP Synthase.

Authors:  Marthe H R Ludtmann; Plamena R Angelova; Natalia N Ninkina; Sonia Gandhi; Vladimir L Buchman; Andrey Y Abramov
Journal:  J Neurosci       Date:  2016-10-12       Impact factor: 6.167

4.  Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo.

Authors:  Shankar J Chinta; Jyothi K Mallajosyula; Anand Rane; Julie K Andersen
Journal:  Neurosci Lett       Date:  2010-09-29       Impact factor: 3.046

Review 5.  α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies.

Authors:  Yvette C Wong; Dimitri Krainc
Journal:  Nat Med       Date:  2017-02-07       Impact factor: 53.440

6.  The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition.

Authors:  Virginie Loeb; Eugenia Yakunin; Ann Saada; Ronit Sharon
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

7.  Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase.

Authors:  Hanock Elkon; Jermy Don; Eldad Melamed; Ilan Ziv; Anat Shirvan; Daniel Offen
Journal:  J Mol Neurosci       Date:  2002-06       Impact factor: 3.444

8.  Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.

Authors:  Latha Devi; Vijayendran Raghavendran; Badanavalu M Prabhu; Narayan G Avadhani; Hindupur K Anandatheerthavarada
Journal:  J Biol Chem       Date:  2008-02-01       Impact factor: 5.157

9.  Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons.

Authors:  A K Reeve; M H R Ludtmann; P R Angelova; E M Simcox; M H Horrocks; D Klenerman; S Gandhi; D M Turnbull; A Y Abramov
Journal:  Cell Death Dis       Date:  2015-07-16       Impact factor: 8.469

Review 10.  Alpha-synuclein biology in Lewy body diseases.

Authors:  Woojin Scott Kim; Katarina Kågedal; Glenda M Halliday
Journal:  Alzheimers Res Ther       Date:  2014-10-27       Impact factor: 6.982

View more
  13 in total

1.  Effect of a post-translational modification mimic on protein translocation through a nanopore.

Authors:  David P Hoogerheide; Philip A Gurnev; Tatiana K Rostovtseva; Sergey M Bezrukov
Journal:  Nanoscale       Date:  2020-05-28       Impact factor: 7.790

2.  Restricting α-synuclein transport into mitochondria by inhibition of α-synuclein-VDAC complexation as a potential therapeutic target for Parkinson's disease treatment.

Authors:  Philip A Gurnev; Megha Rajendran; María Queralt-Martín; William M Rosencrans; Amandine Rovini; Daniel Jacobs; Kaitlin Abrantes; David P Hoogerheide; Sergey M Bezrukov; Tatiana K Rostovtseva
Journal:  Cell Mol Life Sci       Date:  2022-06-19       Impact factor: 9.207

Review 3.  VDAC regulation of mitochondrial calcium flux: From channel biophysics to disease.

Authors:  William M Rosencrans; Megha Rajendran; Sergey M Bezrukov; Tatiana K Rostovtseva
Journal:  Cell Calcium       Date:  2021-01-23       Impact factor: 6.817

4.  α-Synuclein emerges as a potent regulator of VDAC-facilitated calcium transport.

Authors:  William M Rosencrans; Vicente M Aguilella; Tatiana K Rostovtseva; Sergey M Bezrukov
Journal:  Cell Calcium       Date:  2021-02-02       Impact factor: 6.817

5.  Inhibition of α-Synuclein Accumulation Improves Neuronal Apoptosis and Delayed Postoperative Cognitive Recovery in Aged Mice.

Authors:  Yue Li; Yi Yuan; Yitong Li; Dengyang Han; Taotao Liu; Ning Yang; Xinning Mi; Jingshu Hong; Kaixi Liu; Yanan Song; Jindan He; Yang Zhou; Yongzheng Han; Chengmei Shi; Shun Yu; Peng Zou; Xiangyang Guo; Zhengqian Li
Journal:  Oxid Med Cell Longev       Date:  2021-05-28       Impact factor: 6.543

6.  Exploring lipid-dependent conformations of membrane-bound α-synuclein with the VDAC nanopore.

Authors:  David P Hoogerheide; Tatiana K Rostovtseva; Sergey M Bezrukov
Journal:  Biochim Biophys Acta Biomembr       Date:  2021-05-07       Impact factor: 4.019

Review 7.  Targeting the Multiple Physiologic Roles of VDAC With Steroids and Hydrophobic Drugs.

Authors:  Tatiana K Rostovtseva; María Queralt-Martín; William M Rosencrans; Sergey M Bezrukov
Journal:  Front Physiol       Date:  2020-05-07       Impact factor: 4.566

Review 8.  Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment.

Authors:  Giovanna Menduti; Daniela Maria Rasà; Serena Stanga; Marina Boido
Journal:  Front Pharmacol       Date:  2020-11-12       Impact factor: 5.810

Review 9.  A Calcium Guard in the Outer Membrane: Is VDAC a Regulated Gatekeeper of Mitochondrial Calcium Uptake?

Authors:  Paulina Sander; Thomas Gudermann; Johann Schredelseker
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

Review 10.  Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson's Disease: The Emerging Role of VDAC.

Authors:  Pierpaolo Risiglione; Federica Zinghirino; Maria Carmela Di Rosa; Andrea Magrì; Angela Messina
Journal:  Biomolecules       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.